Cellyan Biotechnology (HKPD) Current Deferred Revenue (2024 - 2026)
Cellyan Biotechnology (HKPD) posted quarterly Current Deferred Revenue of $529008.0 for Q3 2025, up 606.5% year-over-year from $74877.0 in Q3 2024, and up 324.88% quarter-over-quarter from $124507.0 in Q1 2025.
Cellyan Biotechnology (HKPD) Current Deferred Revenue (2024 - 2026) Analysis & Trends
Cellyan Biotechnology (HKPD) has reported Current Deferred Revenue for 2 consecutive years, with $529008.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Current Deferred Revenue rose 606.5% year-over-year to $529008.0; the TTM figure through Sep 2025 stood at $529008.0 (up 606.5% YoY), while the FY2025 annual figure was $124507.0, down 34.84% from the prior year.
- Current Deferred Revenue improved to $529008.0 in Q3 2025 per HKPD's latest filing, from $124507.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $529008.0 in Q3 2025 and bottomed at $74877.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Mckesson | 102.57 Bn | 97.41 Bn | 3.69 Bn |
| 2 | Cencora | 61.35 Bn | 58.53 Bn | 3.61 Bn |
| 3 | Cardinal Health | 54.15 Bn | 49.30 Bn | 2.56 Bn |
| 4 | Henry Schein | 10.05 Bn | 9.89 Bn | 1.10 Bn |
| 5 | Akso Health | 671.90 Mn | 671.70 Mn | - |
| 6 | Edap Tms | 154.62 Mn | 133.07 Mn | 7.34 Mn |
| 7 | Accendra Health | 90.69 Mn | 83.04 Mn | 263.41 Mn |
| 8 | 111 | 31.31 Mn | -27.44 Mn | 18.18 Mn |
| 9 | Cosmos Health | 13.28 Mn | 10.84 Mn | 1.51 Mn |
| 10 | Cellyan Biotechnology | 6.70 Mn | 6.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 127,464.00 |
| Sep 30, 2025 | 529,008.00 |
| Mar 31, 2025 | 124,507.00 |
| Sep 30, 2024 | 74,877.00 |
| Mar 31, 2024 | 191,066.00 |